V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330010802 | 330011951 | null | 62 | Palliative (P) | 2017-02-22 | 2017-11-19 | BCG Intravesical | Y | null | 330022355 | AML17 TRIAL |
| 330010803 | 330005655 | 1.6 | null | Curative (C) | 2018-11-13 | 2018-11-19 | GEMCITABINE | N | N | 330022399 | CLADRIBINE |
| 330010804 | 330009087 | null | 71.799 | Palliative (P) | 2016-05-09 | 2016-05-16 | CETUXIMAB + CISPLATIN + FU | N | Y | 330022445 | CETUXIMAB + CISPLATIN + FU |
| 330010805 | 330005657 | 1.6 | 59 | Palliative (P) | 2017-06-25 | 2017-06-26 | Cyclophosphamide oral | 02 | N | 330022445 | IPILIMUMAB |
| 330010806 | 330005661 | 1.6 | 99.9 | Curative (C) | 2017-09-14 | 2017-09-16 | Ifosfamide | 2 | N | 330022491 | CYTARABINE |
| 330010807 | 330009091 | 1.6 | 80.5 | Curative (C) | 2017-02-01 | 2017-02-01 | Gemcitabine + Paclitaxel | 02 | N | 330022493 | ALEMTUZUMAB |
| 330010808 | 330009091 | 0 | 53 | Disease modification (D) | null | 2016-04-27 | IDARUBICIN | null | N | 330022493 | VIDE |
| 330010809 | 330005663 | 1.6 | null | Palliative (P) | 2014-02-11 | 2014-07-25 | Carboplatin + Cetux + FU (>Cycle 2) | N | N | 330022530 | CAPECITABINE + CISPLATIN |
| 330010810 | 330005665 | null | null | Disease modification (D) | null | 2015-05-07 | Capecitabine + Streptozocin | N | null | 330022533 | CISPLATIN + GEMCITABINE |
| 330010811 | 330005667 | 1.56 | 37.2 | Palliative (P) | 2013-10-31 | 2013-11-06 | Bevacizumab 15mg/kg | N | N | 330022626 | CLOFARABINE + CYTARABINE |
| 330010812 | 330005669 | 1.79 | null | Curative (C) | 2013-12-29 | 2013-12-29 | Cyclophosphamide High Dose | N | N | 330022662 | IFOSFAMIDE |
| 330010813 | 330005671 | 0 | 0 | Adjuvant (A) | 2017-06-29 | 2017-08-09 | VIDE | N | null | 330022730 | CAPECITABINE |
| 330010814 | 330005675 | null | 60.5 | Curative (C) | 2018-02-02 | 2018-02-28 | RUXOLITINIB | N | N | 330022807 | DHAP |
| 330010815 | 330010940 | 1.61 | null | Curative (C) | 2018-04-04 | 2018-04-04 | Trastuzumab Subcutaneous | 02 | N | 330022813 | THALIDOMIDE |
| 330010816 | 330009099 | 1.03 | 60.4 | Palliative (P) | null | 2015-08-10 | Enzalutamide | null | null | 330022818 | FLAG |
| 330010817 | 330005679 | 1.84 | 76.1 | Curative (C) | 2015-10-03 | 2015-12-10 | UKALL14- Ph 1 Induction | N | N | 330022832 | CAPE + CARBOPLATIN + CETUXIMAB |
| 330010818 | 330005680 | 1.88 | null | Palliative (P) | 2013-11-07 | 2014-08-03 | ABVD | N | N | 330022859 | CAPECITABINE + CISPLATIN |
| 330010819 | 330005683 | 0 | 51.9 | Curative (C) | 2015-09-25 | 2017-02-28 | Carboplatin + Liposomal Doxorubicin | N | N | 330022880 | MITOTANE |
| 330010820 | 330009101 | 1.73 | 99.9 | Curative (C) | 2016-09-30 | 2017-03-28 | ATG + Busulfan + Fludarabine | N | N | 330022893 | LOMUSTINE + PROCARBAZINE |
| 330010822 | 330005687 | 0.92 | 66.7 | Palliative (P) | 2016-03-01 | 2016-04-16 | Imatinib 400mg | N | null | 330022926 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 330010823 | 330005690 | null | 56.5 | Curative (C) | 2013-12-25 | 2013-12-27 | Cisplatin + Gemcitabine (D 1 & 8) | Y | N | 330022926 | MITOTANE |
| 330010824 | 330005690 | 1.58 | null | Adjuvant (A) | 2017-02-19 | 2017-07-13 | Capecitabine + Streptozocin | N | N | 330022926 | FLUOROURACIL |
| 330010825 | 330013193 | 1.66 | 58.8 | Palliative (P) | 2017-06-03 | 2017-06-05 | VDC | 02 | N | 330022938 | IPILIMUMAB |
| 330010826 | 330005691 | 0 | null | Neo-adjuvant (N) | 2017-12-19 | 2017-12-20 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL | N | null | 330022958 | CVP R |
| 330010828 | 330005697 | 1.82 | null | Curative (C) | 2016-07-11 | 2016-07-18 | Hydroxycarbamide | null | N | 330022992 | CARBOPLATIN + PEMETREXED |
| 330010829 | 330005702 | 1.75 | null | Curative (C) | 2019-02-09 | 2019-02-19 | CARBOPLATIN + Cetuximab + FLUOROURACIL | N | N | 330023021 | IVA |
| 330010830 | 330009111 | 1.71 | 54.3 | Palliative (P) | null | 2015-02-12 | CISPLATIN + DACTINOMYCIN + ETOPOSIDE + METHOTREXATE | null | null | 330023042 | DHAP |
| 330010831 | 330011959 | 0 | 11.3 | null | 2014-11-03 | 2014-12-05 | DACTINOMYCIN + CYCLO + VINCRISTINE | N | N | 330023053 | CISPLATIN + ETOPOSIDE + PACLITAXEL |
| 330010832 | 330009112 | 1.59 | 48.1 | Adjuvant (A) | 2017-03-23 | 2017-04-06 | EMA/CO | N | N | 330023058 | ADE |
| 330010835 | 330005707 | 1.65 | null | Palliative (P) | 2016-11-02 | 2016-11-02 | CAELYX + CYCLOPHOSPHAMIDE + VINCRISTINE | N | N | 330023087 | BEP |
| 330010836 | 330005709 | 1.72 | 87.8 | Neo-adjuvant (N) | 2013-06-02 | 2013-06-02 | Sunitinib | 02 | N | 330023091 | UKALL XII |
| 330010837 | 330009115 | 1.56 | 66.7 | Curative (C) | 2016-04-10 | 2016-07-17 | Triple / Double Intrathecal Therapy | N | N | 330023102 | IDARUBICIN |
| 330010838 | 330009118 | 1.52 | 94.4 | Curative (C) | 2016-04-30 | 2016-07-19 | Doxorubicin + Gemcitabine | Y | N | 330023159 | CYTARABINE |
| 330010839 | 330005715 | 1.49 | null | Curative (C) | 2014-06-23 | 2014-06-25 | MAP + MIFAMURTIDE | 02 | N | 330023161 | MITOTANE |
| 330010840 | 330009120 | 1.61 | 16.4 | Adjuvant (A) | 2015-08-09 | 2015-09-06 | IMATINIB | N | N | 330023226 | EMA |
| 330010841 | 330005719 | 1.61 | 65.4 | Palliative (P) | null | 2017-12-04 | EMA/CO | null | N | 330023240 | IFOSFAMIDE |
| 330010842 | 330005720 | 1.67 | 66 | Disease modification (D) | 2016-01-28 | 2016-01-28 | DHAP | N | N | 330023242 | AML17 TRIAL |
| 330010843 | 330005723 | null | 82 | Curative (C) | 2015-07-29 | 2015-07-31 | CARBOPLATIN + EPIRUBICIN + ETOPOSIDE + MELPHALAN | N | N | 330023248 | TOPOTECAN |
| 330010844 | 330011963 | 174.2 | 76 | Curative (C) | 2018-12-14 | 2019-03-01 | FLUOROURACIL + OXALIPLATIN | 02 | N | 330023268 | OFATUMUMAB |
| 330010845 | 330005724 | 1.86 | 71.5 | Adjuvant (A) | 2017-07-29 | 2017-09-26 | UKALL XII Consolidation 2 & 4 | null | N | 330023274 | IVA |
| 330010846 | 330011964 | null | 60.3 | Palliative (P) | 2018-10-04 | 2018-10-16 | Fludarabine + Melphalan RIC Allo | N | null | 330023279 | IFOSFAMIDE |
| 330010847 | 330005733 | 1.52 | 59.4 | Curative (C) | 2019-01-10 | 2019-02-13 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE | 02 | N | 330023336 | BORTEZOMIB + PANOBINOSTAT |
| 330010848 | 330005734 | 1.68 | 97.15 | Palliative (P) | 2014-12-18 | 2015-01-20 | MAP + MIFAMURTIDE | N | N | 330023338 | UKALL 2011 |
| 330010850 | 330005739 | 1.84 | 17.8 | Disease modification (D) | 2016-05-02 | 2016-05-31 | CVP | N | N | 330023346 | BORTEZOMIB |
| 330010851 | 330009131 | 1.64 | 61.3 | Adjuvant (A) | 2016-06-06 | 2016-06-08 | CVD | 02 | N | 330023349 | EMA/CO |
| 330010852 | 330005741 | 1.7 | 65 | Curative (C) | 2018-06-07 | 2018-06-07 | MA (Cytarabine 3g/m2) | Y | N | 330023353 | ETOPOSIDE + IFOSFAMIDE + MTX |
| 330010853 | 330005749 | 1.77 | 71.45 | Neo-adjuvant (N) | 2016-11-15 | 2016-11-28 | CVP R | N | null | 330023358 | AML16 TRIAL |
| 330010854 | 330009136 | 1.7 | 44 | Curative (C) | 2016-10-18 | 2017-05-21 | MITOTANE | 01 | N | 330023377 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 330010855 | 330005753 | 1.08 | 72.5 | Disease modification (D) | 2013-02-06 | 2013-07-28 | Cladribine (subcut) 5 days | 01 | N | 330023405 | CYCLOPHOSPHAMIDE |
| 330010856 | 330005756 | 1.69 | null | Palliative (P) | 2014-04-19 | 2014-05-05 | MAP + MIFAMURTIDE | N | N | 330023409 | CISPLATIN + ETOPOSIDE + PACLITAXEL |